Short answer
UTAH MEDICAL PRODUCTS INC (UTMD) filed an 8-K current report with the SEC on July 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 99.1 (), Item EX-99.1 (Exhibit EX-99.1). Q2 and first-half 2026 financial results furnished under Item 2.02.
UTAH MEDICAL PRODUCTS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results furnished under Item 2.02
- Exhibit 99.1 contains financial information for three and six months ended June 30, 2026
- Forward-looking statements address 2026 and beyond, creating guidance-related investor relevance
Item 99.1 ·
- Filing references a July 23, 2026 press release covering three and six months ended June 30, 2026
- Forward-looking statements address 2026 and beyond, making guidance and projections the key investor focus
- CEO Kevin L. Cornwell signed the report on July 23, 2026
Item EX-99.1 · Exhibit EX-99.1
- 2Q revenue fell 14.3% to $8.529M; 1H revenue declined 12.3% to $17.252M
- Lost PendoTECH and China distributor sales drove $1.066M of 2Q and $1.923M of 1H revenue shortfall
- Management cut 2026 outlook to a 10–13% revenue decline, making the prior flat-revenue plan unlikely
- 1H operating income fell 17.9% to $5.215M; litigation costs rose $341K and may reach under $1.6M for 2026
- Balance sheet remained debt-free with $87.5M cash and investments, supporting dividends and potential buybacks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UTAH MEDICAL PRODUCTS INC 8-K filings
Get the next UTMD 8-K as it lands
Follow UTMD for push alerts, or ask the research agent what this filing means.